1,139,527 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Purchased by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. bought a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,139,527 shares of the company’s stock, valued at approximately $11,338,000. Adage Capital Partners GP L.L.C. owned about 2.17% of Kodiak Sciences at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in KOD. Price T Rowe Associates Inc. MD lifted its stake in shares of Kodiak Sciences by 10,982.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company’s stock worth $12,622,000 after buying an additional 1,257,063 shares in the last quarter. Silverarc Capital Management LLC raised its holdings in Kodiak Sciences by 100.0% in the 4th quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $9,950,000 after acquiring an additional 500,000 shares during the last quarter. MetLife Investment Management LLC purchased a new position in Kodiak Sciences in the 4th quarter worth approximately $209,000. Dimensional Fund Advisors LP lifted its stake in Kodiak Sciences by 5.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 521,237 shares of the company’s stock worth $5,186,000 after purchasing an additional 26,058 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Kodiak Sciences during the 4th quarter worth approximately $147,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Trading Down 1.9 %

Kodiak Sciences stock opened at $4.11 on Monday. The company has a 50-day moving average price of $3.27 and a 200 day moving average price of $5.44. Kodiak Sciences Inc. has a 12-month low of $1.92 and a 12-month high of $11.60. The stock has a market cap of $216.79 million, a P/E ratio of -1.13 and a beta of 2.40.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.06. As a group, analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.